Private Equity, VC & Investor · vs · Private Equity, VC & Investor
Great Oaks Venture Capital vs Greenoaks
Structured technology and market comparison · 2026
Direct Feature Comparison
Great Oaks Venture Capital · vs · GreenoaksUS seed-stage venture capital firm for early startups.
Concentrated long-term venture investor in technology businesses.
Comparison Analysis
What is the main difference between Great Oaks Venture Capital and Greenoaks?
When comparing Great Oaks Venture Capital and Greenoaks, both platforms operate within the Private Equity, VC & Investor ecosystem. Great Oaks Venture Capital is positioned as US seed-stage venture capital firm for early startups, whereas Greenoaks focuses on Concentrated long-term venture investor in technology businesses. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Great Oaks Venture Capital and Greenoaks?
When evaluating Great Oaks Venture Capital and Greenoaks, enterprise buyers also consider other platforms in Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
Market Signals
Recent Market Signals & Activity: Great Oaks Venture Capital vs Greenoaks
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Great Oaks Venture Capital
Recent Signals
No recent market signals documented for Great Oaks Venture Capital in the current tracking window.
Greenoaks
Recent Signals
- ·CNBC TechnologyPrivacy
Coupang dispute raises U.S. tariff pressure on South Korea
A Republican-led House Judiciary report alleges the South Korean government mounted a targeted campaign against U.S.-headquartered Coupang after a 2025 data breach, prompting calls from some U.S. lawmakers and investors for formal trade investigations and potential tariffs. South Korea disputes the report, defends its actions and the scale of the breach, and says it has engaged with U.S. officials. Investors including Greenoaks and Altimeter urged the U.S. Trade Representative to open a Section 301 probe. The dispute comes amid broader U.S.-South Korea tensions over trade commitments, security cooperation and earlier tariff actions.
- House Judiciary Committee Republicans released a report alleging the South Korean government waged a targeted offensive against Coupang following a data breach.
- South Korea levied a 625 billion won (about $409 million) data-privacy fine on Coupang; Seoul says the breach affected 37.55 million people.
- Investors Greenoaks Capital Partners and Altimeter Capital petitioned the U.S. Trade Representative in January to open a Section 301 investigation into South Korea over its treatment of Coupang.
- ·AINews swyxBehavioral simulation and synthetic populations for decision-making
Simile AI: Behavioral Simulation and Scaling Laws
This podcast episode with Simile co-founder and CEO Joon Sung Park explores the company’s work building behavioral foundation models and synthetic populations for simulation. The discussion covers Simile’s methodology (interviews, transaction/observational data, randomized controlled trials, and post-training on causal mechanisms), validated research (a 1,000-person study where digital twins reproduced human behavior ~85% as accurately as the original humans), enterprise use cases (tens of millions of simulations for Fortune 100 clients like CVS), and the broader ambition to scale multi-agent simulations toward society-scale models. The episode also mentions Simile’s recent Series B at a $2B valuation and funding/backers reported in coverage.
- Simile AI is reported to have a Series B at a $2 billion valuation.
- Simile runs tens of millions of simulations for enterprise customers, including Fortune 100 clients like CVS.
- In a representatively sampled 1,000-person study, Simile’s digital twins reproduced human behavior and attitudes about 85% as accurately as the original humans reproduced their own responses.
- ·techcrunchFundraising
Simile Raises $200M Series B at $2B Valuation
Simile, a startup that builds synthetic/simulated users for marketing and product research, raised $200 million in a Series B at a $2 billion valuation. The round, announced July 30, 2026, was led by Greenoaks with participation from Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures. The raise comes five months after Simile's $100 million Series A led by Index. Simile was founded by Joon Sung Park and counts CVS among its customers. The company positions its technology as a way to simulate user behavior for research and product testing, attracting growing VC interest in the synthetic-user market.
- Simile closed a $200 million Series B at a $2 billion valuation (announced 2026-07-30).
- The Series B was led by Greenoaks with participation from Index, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures.
- The raise comes five months after Simile announced a $100 million Series A led by Index Ventures.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Great Oaks Venture Capital and Greenoaks share across the market ecosystem.